The board of Sirnaomics Ltd. announced that the re-election of each of Dr. David Mark Evans and Dr. Edward Yongxiang Wang as an executive Director were not passed at the AGM held on June 20, 2024, each of Dr. Evans and Dr. Wang has retired as an executive Director with effect from the conclusion of the AGM in accordance with the fourth amended and restated memorandum of association and articles of association of the Company. Dr. Evans will remain as the Head of Drug Discovery and Collaboration of the Group, and Dr. Wang will remain as the Chief Production Officer of the Group. The Board announced that as the ordinary resolution regarding the re-election of Mr. Fengmao Hua as an independent non-executive Director was not passed at the AGM held on June 20, 2024, Mr. Hua has retired as an independent non-executive Director with effect from the conclusion of the AGM in accordance with the Articles of Association.

Following the retirement of Mr. Hua, he will cease to be a member of the audit committee of the Company, and the chairman and a member of the nomination committee of the Company. Each of Dr. Evans, Dr. Wang and Mr. Hua has confirmed that each of them had no disagreement with the Board, and there were no other matters relating to their respective retirement that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.